BCI Pioneers Coalition issues 13 recommendations for brain implant trials
The BCI Pioneers Coalition issued 13 recommendations to strengthen patient agency in implanted brain-computer interface trials, covering post-trial care, informed consent and neural data privacy. The report matters because ALS and tetraplegia patients may have limited alternatives and long-term stakes in experimental brain devices. It is a policy document based on participant accounts, not clinical trial evidence.
The BCI Pioneers Coalition released a report last week outlining 13 recommendations for startups, researchers and regulators designing trials of implanted brain-computer interfaces, or BCIs. The group was co-founded by Ian Burkhart, who was implanted with a device at Ohio State University in 2014 that helped him move his arm, and other early study participants. The report focuses on post-trial care, informed consent and neural data privacy, reflecting concerns from people with tetraplegia or ALS who often join trials to restore communication, mobility or autonomy.
The recommendations are based on participant discussions rather than a clinical trial result. Burkhart said early participants felt they had little say in how trials were conducted. In his 2014 Ohio State study, he said the institutional review board proposed removing the device when funding issues threatened continuation, with possible reimplantation later. He described that as disruptive and said it reduced his role to something like a lab rat. He also said consent forms often protect researchers and institutions more than participants, especially when re-consenting, or agreeing to continue a study.
The report arrives as implanted BCIs move from small proof-of-concept studies toward a larger neurotechnology industry with startups, investors and multiple clinical trials testing safety and efficacy. Because devices are implanted in the brain and can remain in use for years, participant concerns extend beyond a single consent signature to long-term access, explantation and data rights. UCLA ethicist Anna Wexler said there is no established solution, citing possible insurance policies, escrow arrangements and institutional commitments that have not yet become standard.
For people with ALS or tetraplegia, implanted BCIs can be among the few routes to restoring hand movement, speech or family communication. The report's emphasis on agency matters because participants may have limited alternatives and can be psychologically attached to devices that restore function. The report is a policy document based on participant accounts, not a clinical trial; it can identify concerns but cannot show whether the recommendations improve care. Burkhart wants clearer expectations on brain data and care after explantation, or removal. Future studies should test whether such changes improve participant safety, data control and post-trial care.
Patients with ALS or tetraplegia may rely on implanted brain-computer interfaces as a last-ditch route to communication or movement, so unclear consent, data rights and post-trial care can affect safety, trust and access.
Sources (1)
- [1]Patients have little say in how brain implant trials are done. Ian Burkhart wants to change that(https://www.statnews.com/2026/11/20/ian-burkhart-how-brain-implant-trials-can-serve-patients-better/?utm_campaign=rss)